Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW)

Etorro trading 970x250

About Adial Pharmaceuticals, Inc. WT EXP 073123

Address:

Adial Pharmaceuticals, Inc. WT EXP 073123 News and around…

Latest news about Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) common stock and company :

Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate
21 Oct, 2021 Yahoo! Finance

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs. PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications. PNV-5030 has demonstrated more than 50 times greate

Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain
21 Oct, 2021 Yahoo! Finance

Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction Clinical trial expected to commence in 2022 CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive data in a pre-clinical mo

Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
18 Oct, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer and President of Adial Pharmaceuticals, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 at the Wyndham Gr

Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021
05 Oct, 2021 Yahoo! Finance

CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually this week, October 5 - 8, 2021.

36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
04 Oct, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Fall Harvest - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, October 5th, 2021, with company presentations beginning at 8:30 am Eastern Time.

Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Peri
30 Sep, 2021 FinancialContent
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
30 Sep, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces that greater than 50% of patients expected to complete the ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes re

Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
28 Sep, 2021 FinancialContent

Collaboration targeting development of new adenosine formulations that can be absorbed transdermally

Adial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
15 Sep, 2021 FinancialContent
Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors
13 Sep, 2021 Yahoo! Finance

HERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB: SYSX) (“Sysorex” or the “Company”), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the Company’s Board of Directors and as Chair of the Board’s Audit Committee. The Company also expanded the size of its Board to five directors and established its Audit Committee. Mr. Stilley is the Chief Executive Officer of Adial Pharmaceuticals,

Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
31 Aug, 2021 FinancialContent

ONWARD trial enrollment closed; trial completion expected in Q1 2022

Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
20 Aug, 2021 FinancialContent
Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments
20 Aug, 2021 FinancialContent
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
12 Aug, 2021 FinancialContent
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
10 Aug, 2021 FinancialContent
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
05 Aug, 2021 FinancialContent

Financing fully funds ONWARD™ Phase 3 trial until data read-out

Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com
29 Jul, 2021 FinancialContent
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
14 Jul, 2021 FinancialContent
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
07 Jul, 2021 FinancialContent
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
06 Jul, 2021 FinancialContent
Adial Joins Russell Microcap® Index
28 Jun, 2021 FinancialContent
Adial Pharmaceuticals Provides Regulatory and Development Update
24 Jun, 2021 FinancialContent
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test
22 Jun, 2021 FinancialContent

The Company believes the genetic companion diagnostic test for AD04 for Alcohol Use Disorder represents a multi-billion dollar potential market opportunity

Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Addiction
07 Jun, 2021 FinancialContent
Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
03 Jun, 2021 FinancialContent
Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder
18 May, 2021 FinancialContent
Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel
17 Mar, 2021 FinancialContent

Discusses long-term effects of COVID-19 pandemic on mental health and addiction

Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
15 Mar, 2021 FinancialContent
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
26 Feb, 2021 FinancialContent

Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) is a NASDAQ Common Stock listed in ,

970x250